Deinove 2018 Annual Results: a year of significant progress - Nasdaq

Deinove 2018 Annual Results: a year of significant progress  Nasdaq

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium difficile,.



Comments

Popular posts from this blog

Roseola rash: symptoms, pictures, and treatment - Medical News Today